|
|
|
Real Estate News Releases
|
(EMAILWIRE.COM, January 30, 2012 ) Belize City, Belize -- Publishers of daily newsletter xtremepicks.com (http://www.xtremepicks.com) looks at Cannibus Science (CBIS) and Fuse Science (DROP)
On the backs of xtremepicks milestone week topping over 150,000 Twitter users, they have opened the invitation for their members to jump in the xtremepicks chat circle now available on SKYPE.
ItÂ’s free, and itÂ’s easy to join. Skype can be downloaded at
http://www.skype.com/intl/en-us/get-skype
Skype name: xtremepicks
Send Xtremepicks a request now and get in on the xtreme action!
CANNIBUS SCIENCE (CBIS)
CBIS recently announced that is set to begin FDA Investigational New Drug (IND) Application Process. This is a monster step forward for CBIS, and investors jumping in at this low price point stands to make out with monster gains.
They key to this next phase is that once Cannabis ScienceÂ’s application for a FDA license is approved, their model forecasts shows average sales of $279,120,000 in annual sales and revenue of each of their cannabis-extract based formulations.
The potential to increase Earnings to $65,740,000 in 2014
CBIS recently issued its fiscal 2012 earnings guidance. The company says sales for 2012 are forecasted to be $6,846,000, while arguing that the company’s revenues have “the potential to increase to $65,740,000 in 2014.”
CBIS closed at $0.047 up 17% from xtremepicks twitter alert last week and the stock remains super liquid for investors. With recent consolidation, CBIS has established a firm footing on support levels and ready for the next leg up to “blue Sky” territory.
CBIS Stock Chart
Xtremepicks continues to accumulate a position in CBIS over the next few weeks and their sights are holding for the long term view.
There is too much potential in CBIS not to be part of this “history in the making” play!
With active press releases coming out of the company, we expect very active trading session for weeks to come:
Cancer Patient Success Prompts Cannabis Science To Begin FDA Investigational New Drug (IND) Application ProcessBusiness Wire(Wed Jan 25)
Cannabis Science Updates Latest Remarkable Follow up Photographs Received from 3rd Cancer PatientBusiness Wire(Tue Jan 24)
Cannabis Science Updates Second Medical Cannabis Cancer Patient Suffering from Squamous Cell Carcinoma Photo-documents Cannabis Extracts Killing Cancerous TumorBusiness Wire(Thu Jan 19)
Generex Biotechnology and Cannabis Science Look to Make Headway in Lucrative Cancer Drug MarketMarketwire(Thu Jan 12)
Cannabis Science Reports Apparent Success for 3rd Self-Medicated Cancer PatientPR Newswire(Wed Jan 11)
Cannabis Science Reports Apparent Success For 3rd Self-Medicated Cancer PatientBusiness Wire(Wed Jan 11)
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
FUSE SCIENCE
DROP‘s product demand have been booming and no wonder with endorsements like Tiger Woods, David “Big Papi” Ortiz, and Arian Foster.
DROP‘s recent launch on Amazon.com caught the attentions of many athletes around the world selling out their product in record time.
As the result, DROP‘s solid management and quick response to the exponential growth recently announce a partnership with Smart Warehousing that will definitely give a boost to DROP’s sales and inventory management.
Fuse Science Opens New Headquarters and Partners with North American Supply Chain Expert Smart Warehousing to Support Growth
“Our business is advancing rapidly and we’re taking every action necessary to stay in front of our growth curve,” said Brian Tuffin, Chief Executive Officer
“These moves advance our company beyond the temporary overflow challenges due to EnerJel™ demand at launch and set the stage for marked progress against our corporate objectives in 2012,” added Tuffin. “We remain extremely confident about the future ahead of this company as we advance our licensing efforts, continued growth of EnerJel™ and the launch of our HydroFuse™ and PowerFuse™ drop technology later this year.”
DROP last traded at $0.421 and xtremepicks is on high news alert as xtremepicks anticipate more monster updates to be unleashed soon. Smart buyers are positioning themselves for this trigger breakout.
About FUSE Science
Fuse Science Inc. is a company made from leading scientific minds and consumer product industry experts with a common goal to raise the standard of product performance through science in key multi-billion dollar categories. We leverage our global leading science to completely change the rules of the game. WeÂ’ve discovered through a combination of pending patents and trade secrets that we can now encapsulate nutrients, actives and other molecules at a far greater concentration than any time in historyÂ… What use to require consuming an 8 oz energy drink can be done with safer formulations and faster results in a single drop.
Fuse Science breakthroughs can deliver Energy, Nutrition, Medication, Skin Care and an endless number of other products with faster absorption, quicker results and better efficacy.
For members who have been with Xtremepicks from the start knows what xtremepicks is all about and their track record is best in class.
For those who are new to xtremepicks will also realize the same and their stats just shows how they get it done.
60,659 Alexa Rating!
151,255 Twitter followers
Huge membership base that continues to grow daily
Xtremepicks is everywhere from Facebook to Google buzz
Xtremepicks is listed in numerous countries in Europe, Asia, and North America
Companies with a solid future needs good exposure and xtremepicks delivers. Their records speak for itself. Check out their most recent winners:
DROP +83,000% gains, BRYN +700% gains, and IFHR +733% gains.
More Xtremepicks winning picks! http://www.xtremepicks.com/76-2
While there are many newsletters out there, very few can give you solid and consistent results but only ONE can give you xtremepicks!
Keep your eyes peeled for the latest updates on our twitter page, facebook page, and our website at http://www.xtremepicks.com.
About Xtremepicks.com
Xtremepicks.com team of excellence strives to find undervalued, good momentum stock plays. Xtremepicks.com provide market awareness services for small to mid-cap stocks with daily and special newsletters to keep you informed of the latest movers.
Xtremepicks.com penny stock newsletter is your trading connection and remember to always do your own research, use stop loss orders to protect yourself, and book your profits when in a position to do so.
Xtremepicks.com penny stock newsletter profiles are not a solicitation or recommendation to buy, sell or hold securities and is not offering securities for sale. Verify all claims and do your own due diligence. . Xtremepicks did not receive any compensation for DROP, CTON, RIMM and may be buyers in the open market. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved
Directglobalmedia.com
Max Gordon
6479227508
contact@directglobalmedia.com 
|
|
|
|
Real Estate News by Sector
|
|
|
|
|
